MNG1138
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.464
- INTERFERON_GAMMA_RESPONSE+0.459
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.439
- IL6_JAK_STAT3_SIGNALING+0.374
- ALLOGRAFT_REJECTION+0.356
- INFLAMMATORY_RESPONSE+0.328
- COAGULATION+0.285
- UV_RESPONSE_DN+0.283
- KRAS_SIGNALING_UP+0.281
- APICAL_SURFACE+0.239
Top 10 suppressed
- MITOTIC_SPINDLE-0.333
- NOTCH_SIGNALING-0.311
- G2M_CHECKPOINT-0.295
- MYC_TARGETS_V2-0.280
- E2F_TARGETS-0.240
- WNT_BETA_CATENIN_SIGNALING-0.208
- GLYCOLYSIS-0.157
- ESTROGEN_RESPONSE_EARLY-0.155
- UV_RESPONSE_UP-0.152
- P53_PATHWAY-0.145
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-50-5049-01A-01R-1628-07 | — | cohortA1 | 0.809 |
| 2 | MNG1132 | — | — | 0.794 |
| 3 | MBCProject_5809_T1_RNA | — | C | 0.786 |
| 4 | MDT-AP-2900 | Med | Medulloblastoma | 0.782 |
| 5 | TCGA-BH-A0EB-01A-11R-A034-07 | — | B | 0.775 |
| 6 | TCGA-44-3918-01A-01R-1107-07 | — | cohortA1 | 0.774 |
| 7 | TCGA-CQ-5325-01A-01R-1686-07 | — | — | 0.774 |
| 8 | TCGA-A8-A0A7-01A-11R-A00Z-07 | — | D | 0.766 |
| 9 | SRR8526727 | — | cohortMD2 | 0.765 |
| 10 | MNG561 | — | — | 0.763 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.464 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.459 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.439 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.374 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.356 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.328 | Idelalisib | — uncovered |
| COAGULATION | 0.285 | Binimetinib | — uncovered |
| UV_RESPONSE_DN | 0.283 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.281 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.239 | Temsirolimus | — uncovered |
| PANCREAS_BETA_CELLS | 0.226 | Cobimetinib | — uncovered |
| COMPLEMENT | 0.201 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.162 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.131 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.129 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.118 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.111 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.088 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.080 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.079 | Inavolisib | — uncovered |